Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITPR3 | Q14573 | 8/20 | 1.00 |
| ▸ | ITPR2 | Q14571 | 4/20 | 0.94 |
| ▸ | ITPR1 | Q14643 | 4/20 | 0.94 |
| ▸ | INPP5A | Q14642 | 2/20 | 0.80 |
| ▸ | INPPL1 | O15357 | 1/20 | 0.80 |
| ▸ | AKT1 | P31749 | 1/20 | 0.80 |
| ▸ | SMPD1 | P17405 | 1/20 | 0.70 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Atrinositol SCHEMBL134177 | 1.00 | ITPR3 (1.00) | ITPR3ITPR2ITPR1INPP5AINPPL1 | |
| Atrinositol SCHEMBL9022890 | 1.00 | ITPR3 (1.00) | ITPR3ITPR2ITPR1INPP5AINPPL1 | |
| Atrinositol SCHEMBL636077 | 1.00 | ITPR3 (1.00) | ITPR3ITPR2ITPR1INPP5AINPPL1 | |
| Atrinositol SCHEMBL9489238 | 1.00 | ITPR3 (1.00) | ITPR3ITPR2ITPR1INPP5AINPPL1 | |
| Atrinositol SCHEMBL888326 | 1.00 | ITPR3 (1.00) | ITPR3ITPR2ITPR1INPP5AINPPL1 | |
| Atrinositol SCHEMBL30474862 | 1.00 | ITPR3 (1.00) | ITPR3ITPR2ITPR1INPP5AINPPL1 | |
| Atrinositol SCHEMBL29370539 | 1.00 | ITPR3 (1.00) | ITPR3ITPR2ITPR1INPP5AINPPL1 | |
| Atrinositol SCHEMBL180074 | 1.00 | ITPR3 (1.00) | ITPR3ITPR2ITPR1INPP5AINPPL1 | |
| Atrinositol SCHEMBL26683544 | 0.97 | ITPR3 (0.95) | ITPR3ITPR2ITPR1INPP5AINPPL1 | |
| SCHEMBL405897 | 0.97 | ITPR3 (1.00) | ITPR3ITPR2ITPR1INPP5AINPPL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 430 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3166572-B1 | ANTI-CALCULUS ORAL COMPOSITIONS | PROCTER & GAMBLE (US) | 2019-05-01 | — | — | EP | claimed |
| EP-3166572-A1 | ANTI-CALCULUS ORAL COMPOSITIONS | The Procter and Gamble Company (US) | 2017-05-17 | — | — | EP | claimed |
| US-20160074421-A1 | METHOD FOR THE TREATMENT OF DISEASES CAUSED BY HAEMORRHAGIC VIRUSES AND COMPOUNDS FOR USE IN SAID TREATMENT | SIRÈN MATTI (FI) | 2016-03-17 | — | — | US | claimed |
| WO-2016004597-A1 | ANTI-CALCULUS ORAL COMPOSITIONS | THE PROCTER & GAMBLE COMPANY (US) | 2016-01-14 | — | — | WO | claimed |
| US-20160008238-A1 | Anti-Calculus Oral Compositions | THE PROCTER & GAMBLE COMPANY | 2016-01-14 | — | — | US | claimed |
| EP-1998743-B1 | Oral care compositions providing enhanced whitening and stain prevention | PROCTER & GAMBLE (US) | 2013-06-26 | — | — | EP | claimed |
| US-20100261682-A1 | Method and Means for the Treatment of Cachexia | BIONERIS AB | 2010-10-14 | — | — | US | claimed |
| EP-2187892-A1 | METHOD AND MEANS FOR THE TREATMENT OF CACHEXIA | Bioneris AB (SE) | 2010-05-26 | — | — | EP | claimed |
| WO-2009038533-A1 | METHOD AND MEANS FOR THE TREATMENT OF CACHEXIA | BIONERIS AB (SE) | 2009-03-26 | — | — | WO | claimed |
| EP-1998743-A1 | ORAL CARE COMPOSITIONS PROVIDING ENHANCED WHITENING AND STAIN PREVENTION | The Procter and Gamble Company (US) | 2008-12-10 | — | — | EP | claimed |
| US-5846957-A | Use of an ester of inositoltrisphosphate for the preparing of medicaments | PERSTORP AB (SE) | 1998-12-08 | — | — | US | claimed |
| WO-1997023229-A1 | THE USE OF AN ESTER OF INOSITOLTRISPHOSPHATE FOR THE PREPARING OF MEDICAMENTS | PERSTORP AB (SE) | 1997-07-03 | — | — | WO | claimed |
| EP-0730461-A1 | THE USE OF AN ESTER OF INOSITOLTRISPHOSPHATE FOR THE PREPARING OF AN ANALGETIC MEDICAMENT | PERSTORP AB (SE) | 1996-09-11 | — | — | EP | claimed |
| EP-0730460-A1 | THE USE OF AN ESTER OF INOSITOLTRISPHOSPHATE FOR THE TREATMENT OF INFLAMMATORY CONDITIONS | PERSTORP AB (SE) | 1996-09-11 | — | — | EP | claimed |
| WO-1995014477-A1 | THE USE OF AN ESTER OF INOSITOLTRISPHOSPHATE FOR THE TREATMENT OF INFLAMMATORY CONDITIONS | PERSTORP AB (SE) | 1995-06-01 | — | — | WO | claimed |
| WO-1995014476-A1 | THE USE OF AN ESTER OF INOSITOLTRISPHOSPHATE FOR THE PREPARING OF AN ANALGETIC MEDICAMENT | PERSTORP AB (SE) | 1995-06-01 | — | — | WO | claimed |
| US-5330979-A | Administering to treat nervous system and cardiovascular disorders | PERSTORP AB (SE) | 1994-07-19 | — | — | US | claimed |
| US-5128332-A | Method of treating cardiovascular diseases using inositoltrisphosphate | PERSTORP AB (SE) | 1992-07-07 | — | — | US | claimed |
| US-5057507-A | Method of alleviating bone damage with inositoltriphosphate | PERSTORP AB (SE) | 1991-10-15 | — | — | US | claimed |
| US-4873355-A | Process for regioselectively preparing phosphorylated inositols and other cyclitols | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1989-10-10 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100261682-A1 | Method and Means for the Treatment of Cachexia | PYGM, GYS1, CPT1B | ITPR3 3281/4885ITPR2 3937/4885ITPR1 3918/4885 |
| US-20160074421-A1 | METHOD FOR THE TREATMENT OF DISEASES CAUSED BY HAEMORRHAGIC VIRUSES AND COMPOUNDS FOR USE IN SAID TREATMENT | TTPA, LPO, HADHB | ITPR3 4534/4885ITPR2 4560/4885ITPR1 4377/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.